Traditionally, treatment decisions have been based on tumor histology and the status of three main biomarkers: Estrogen receptor 1 (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [2]. The gene discussed is ERBB2; the disease is neoplasm.